Heart Attack

New HeartFlow RoadMap™ Analysis Now Available in U.S. to Assist CT Readers in Identifying Coronary Artery Narrowings

Non-invasive, AI-enabled product helps CT readers to accurately*, efficiently, and consistently identify narrowings in the coronary arteries, advancing the HeartFlow…

2 years ago

HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences

Financing will further drive commercial scale for HeartFlow’s AI-enabled portfolio of precision heart care productsMOUNTAIN VIEW, Calif., April 06, 2023…

2 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical…

2 years ago

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

Company teams up with Novartis on Lipoprotein(a) education for 23andMe customersSOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) --…

2 years ago

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to…

2 years ago

MemorialCare Saddleback Medical Center Celebrated the Topping Out of $80M Innovative Women’s Health Pavilion

40,000-square-foot building opening in 2023, will transform women’s healthcare in south Orange County MemorialCare Saddleback Medical Center Celebrates the Forthcoming…

2 years ago

ProSomnus® Enrolls First Participant in Study Evaluating Safety and Efficacy of ProSomnus EVO™ in Treating Severe Obstructive Sleep Apnea

SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices…

2 years ago

Study Published in “Military Medicine” Reports 88% Success Treating Obstructive Sleep Apnea Patients with Precision Oral Appliance Therapy

Treatment with Precision Oral Appliance Therapy Demonstrated Significant Improvements in Apnea-Hypopnea Events, Respiratory Disturbances, Oxygen Saturation, REM Sleep, Sleep Efficiency…

2 years ago

ProSomnus® Debuts as Publicly Traded Company Focused on Disrupting Obstructive Sleep Apnea Treatment Market with Patient-preferred Precision Oral Appliance Therapy Devices

Completes business combination with Lakeshore Acquisition I Corp. ProSomnus common stock will trade on Nasdaq Capital Market under ticker symbol…

2 years ago

ProSomnus Reports Third Quarter Financial Results and Provides Corporate Update

Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022…

2 years ago